Avaliação dos gastos realizados pelo Ministério da Saúde commedicamentos de alto custo utilizados no tratamento da drc por pacientesdo SUS no Estado de Minas Gerais 2000 a 2004

Abstract

Introdution: The chronic kidney disease is represented for irreversible and slow loss of kidney functions. In Brazil, the treatment for this illness is supplied by Unique Health System (SUS) and included dialyses and kidney transplant, beyond the use of medicines for treatment of resulting complications of kidney diminution of function. In 2000, 6% of thetotal expenses with procedures in SUS were spent with high cost medicines. To this scenario adds the problem of the drugs industry be high internationalized and that the market is dominated by some few multinational. So, given that the medicines utilized by patients indialysis are considered of high cost and the need of rationalization of the financial resources destined to the health in the country,studies detailed about the subject proposed become of importance to understand the economic impact of the use of these medicines in the public health of the country. Objective: Analyse the expenses of the Department of the Health with exceptional medicines used by patients in dialysis in treatment of the chronic kidney deficiency, in Minas Gerais from 2000 to 2004. Results: In this study, was observed that the Department of Health expenses with procedures of high cost in Brazil was around R$ 8.6 billion by 2000 to 2004 and around R$ 780 millions were spent with high cost medicines.Minas Gerais was the fourth state in expenses with this kind of medicines. Epoetin represents the bigger percentage of expense in the state (88%), being entirely imported. The profile of the SUS/MG users that utilized some medicine for treatment of CRD in analyzed period it was observed that were of the male sex, with medium age of 47 years and had the arterial hypertension/cardiovascular disease, as main cause identified of CRD. So, the most frequency entrance modality in TRS was hemodialysis and the place in MG with most resident users in the beginning of the treatament was the center region, considered to mostdeveloped of the state. The medium individual expenses analysis considering monthly demonstrated a smaller tendency of expense with: more advanced age; indeterminate causes of CRD; that initiated RRP in kidney transplant or that did not have a determined modality; that utilized therapeutic plans including hydroxide of iron; and residents in place with smaller IDH-M in the beginning of the treatment. Conclusion: The study achieved the main objective to evaluate the expenses with medicines utilized in CRD for SUS/MG users. It was demonstrate that is possible the construction of databases centered in the patient obtained from administrative dates disposed by national information systems (SIA/SIH/SIM). Databases centered in patients permits important informations for rational management of SUS resources considering users profile and utilization and effectiveness profile of the services.